• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

相似文献

1
Genomic profiling of multifocal intrahepatic cholangiocarcinoma reveals intraindividual concordance of genetic alterations.多灶性肝内胆管癌的基因组分析揭示了个体内遗传改变的一致性。
Carcinogenesis. 2021 Apr 17;42(3):436-441. doi: 10.1093/carcin/bgaa124.
2
Prognostic value of lymphadenectomy for long-term outcomes in node-negative intrahepatic cholangiocarcinoma: A multicenter study.淋巴结清扫术对淋巴结阴性的肝内胆管癌长期预后的预测价值:一项多中心研究。
Surgery. 2019 Dec;166(6):975-982. doi: 10.1016/j.surg.2019.06.025. Epub 2019 Aug 14.
3
Prognosis after resection for hepatitis B virus-associated intrahepatic cholangiocarcinoma.乙型肝炎病毒相关性肝内胆管癌切除术后的预后
World J Gastroenterol. 2015 Jan 21;21(3):935-43. doi: 10.3748/wjg.v21.i3.935.
4
ACGH detects distinct genomic alterations of primary intrahepatic cholangiocarcinomas and matched lymph node metastases and identifies a poor prognosis subclass.ACGH 检测原发性肝内胆管癌及其匹配的淋巴结转移的独特基因组改变,并确定预后不良的亚类。
Sci Rep. 2018 Jul 13;8(1):10637. doi: 10.1038/s41598-018-28941-6.
5
Clinical impact of lymph node dissection in surgery for peripheral-type intrahepatic cholangiocarcinoma.淋巴结清扫术在外周型肝内胆管细胞癌手术中的临床意义。
Surg Today. 2012 Jan;42(2):147-51. doi: 10.1007/s00595-011-0057-9. Epub 2011 Nov 30.
6
Routine lymph node dissection may be not suitable for all intrahepatic cholangiocarcinoma patients: results of a monocentric series.常规淋巴结清扫术可能并不适用于所有肝内胆管细胞癌患者:一项单中心系列研究的结果。
World J Gastroenterol. 2013 Dec 21;19(47):9084-91. doi: 10.3748/wjg.v19.i47.9084.
7
Cholangiocarcinoma Heterogeneity Revealed by Multigene Mutational Profiling: Clinical and Prognostic Relevance in Surgically Resected Patients.多基因突变异质性揭示胆管癌:手术切除患者的临床及预后相关性
Ann Surg Oncol. 2016 May;23(5):1699-707. doi: 10.1245/s10434-015-5046-6. Epub 2015 Dec 30.
8
Genomic profiling of intrahepatic cholangiocarcinoma: refining prognosis and identifying therapeutic targets.肝内胆管癌的基因组分析:优化预后并确定治疗靶点。
Ann Surg Oncol. 2014 Nov;21(12):3827-34. doi: 10.1245/s10434-014-3828-x. Epub 2014 Jun 3.
9
Intrahepatic cholangiocarcinoma: prognostic factors after surgical resection.肝内胆管癌:手术切除后的预后因素
World J Surg. 2009 Jun;33(6):1247-54. doi: 10.1007/s00268-009-9970-0.
10
Surgical treatments and prognoses of patients with combined hepatocellular carcinoma and cholangiocarcinoma.肝细胞癌合并胆管癌患者的外科治疗及预后
Ann Surg Oncol. 2009 Mar;16(3):623-9. doi: 10.1245/s10434-008-0278-3. Epub 2009 Jan 6.

引用本文的文献

1
Concordance in Oncogenic Alterations Between the Primary Tumor and Advanced Disease: Insights Into the Heterogeneity of Intrahepatic Cholangiocarcinoma.原发性肿瘤和晚期疾病中致癌改变的一致性:肝内胆管癌异质性的见解。
JCO Precis Oncol. 2024 Feb;8:e2300534. doi: 10.1200/PO.23.00534.
2
Suppressive effects of umbilical cord mesenchymal stem cell-derived exosomal miR-15a-5p on the progression of cholangiocarcinoma by inhibiting CHEK1 expression.脐带间充质干细胞衍生的外泌体miR-15a-5p通过抑制CHEK1表达对胆管癌进展的抑制作用
Cell Death Discov. 2022 Apr 15;8(1):205. doi: 10.1038/s41420-022-00932-7.
3
Intrahepatic cholangiocarcinoma: Tumour heterogeneity and its clinical relevance.肝内胆管癌:肿瘤异质性及其临床相关性。
Clin Mol Hepatol. 2022 Jul;28(3):396-407. doi: 10.3350/cmh.2021.0287. Epub 2022 Jan 14.
4
Biliary Tract Cancers: Treatment Updates and Future Directions in the Era of Precision Medicine and Immuno-Oncology.胆道癌:精准医学与免疫肿瘤学时代的治疗进展与未来方向
Front Oncol. 2021 Nov 15;11:768009. doi: 10.3389/fonc.2021.768009. eCollection 2021.
5
Current challenges to underpinning the genetic basis for cholangiocarcinoma.当前支持胆管癌遗传基础的挑战。
Expert Rev Gastroenterol Hepatol. 2021 May;15(5):511-526. doi: 10.1080/17474124.2021.1915128. Epub 2021 Apr 23.

本文引用的文献

1
Pemigatinib for previously treated, locally advanced or metastatic cholangiocarcinoma: a multicentre, open-label, phase 2 study.培米替尼治疗既往治疗过的局部晚期或转移性胆管癌:一项多中心、开放标签、2 期研究。
Lancet Oncol. 2020 May;21(5):671-684. doi: 10.1016/S1470-2045(20)30109-1. Epub 2020 Mar 20.
2
Prognostic Impact of Tumor Multinodularity in Intrahepatic Cholangiocarcinoma.肿瘤多结节性对肝内胆管癌的预后影响。
J Gastrointest Surg. 2019 Sep;23(9):1801-1809. doi: 10.1007/s11605-018-4052-y. Epub 2018 Nov 26.
3
Emerging role of precision medicine in biliary tract cancers.精准医学在胆道癌中的新兴作用。
NPJ Precis Oncol. 2018 Oct 3;2:21. doi: 10.1038/s41698-018-0064-z. eCollection 2018.
4
Patterns of Distribution of Hepatic Nodules (Single, Satellites or Multifocal) in Intrahepatic Cholangiocarcinoma: Prognostic Impact After Surgery.肝内胆管细胞癌中单发性、卫星灶或多灶性肝结节分布模式:手术治疗后的预后影响。
Ann Surg Oncol. 2018 Nov;25(12):3719-3727. doi: 10.1245/s10434-018-6669-1. Epub 2018 Aug 7.
5
Comprehensive Molecular Profiling of Intrahepatic and Extrahepatic Cholangiocarcinomas: Potential Targets for Intervention.肝内和肝外胆管癌的全面分子分析:干预的潜在靶点。
Clin Cancer Res. 2018 Sep 1;24(17):4154-4161. doi: 10.1158/1078-0432.CCR-18-0078. Epub 2018 May 30.
6
Intrahepatic cholangiocarcinoma: can imaging phenotypes predict survival and tumor genetics?肝内胆管癌:影像学表型能否预测生存和肿瘤遗传学?
Abdom Radiol (NY). 2018 Oct;43(10):2665-2672. doi: 10.1007/s00261-018-1505-4.
7
Phase II Study of BGJ398 in Patients With FGFR-Altered Advanced Cholangiocarcinoma.BGJ398 治疗 FGFR 改变的晚期胆管癌患者的 II 期研究。
J Clin Oncol. 2018 Jan 20;36(3):276-282. doi: 10.1200/JCO.2017.75.5009. Epub 2017 Nov 28.
8
Systemic and Adjuvant Therapies for Intrahepatic Cholangiocarcinoma.肝内胆管癌的全身治疗和辅助治疗
Cancer Control. 2017 Jul-Sep;24(3):1073274817729241. doi: 10.1177/1073274817729241.
9
New Horizons for Precision Medicine in Biliary Tract Cancers.胆道肿瘤精准医学的新视野。
Cancer Discov. 2017 Sep;7(9):943-962. doi: 10.1158/2159-8290.CD-17-0245. Epub 2017 Aug 17.
10
Insertion-and-deletion-derived tumour-specific neoantigens and the immunogenic phenotype: a pan-cancer analysis.插入缺失衍生的肿瘤特异性新抗原和免疫表型:泛癌分析。
Lancet Oncol. 2017 Aug;18(8):1009-1021. doi: 10.1016/S1470-2045(17)30516-8. Epub 2017 Jul 7.

多灶性肝内胆管癌的基因组分析揭示了个体内遗传改变的一致性。

Genomic profiling of multifocal intrahepatic cholangiocarcinoma reveals intraindividual concordance of genetic alterations.

机构信息

Department of Surgery, CHA Bundang Medical Center, CHA University, Seongnam, Republic of Korea.

Department of Surgical Oncology, Houston, TX, USA.

出版信息

Carcinogenesis. 2021 Apr 17;42(3):436-441. doi: 10.1093/carcin/bgaa124.

DOI:10.1093/carcin/bgaa124
PMID:33200197
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8052956/
Abstract

In multifocal intrahepatic cholangiocarcinoma (IHC), intrahepatic metastases (IM) represent a contraindication to surgical resection, whereas satellite nodules (SN) do not. However, no consensus criteria exist to distinguish IM from SN. The purpose of this study was to determine genetic alterations and clonal relationships in surgically resected multifocal IHC. Next-generation sequencing of 34 spatially separated IHC tumors was performed using a targeted panel of 201 cancer-associated genes. Proposed definitions in the literature were applied of SN located in the same liver segment and ≤2 cm from the primary tumor; and IM located in a different liver segment and/or >2 cm from the primary tumor. Somatic point mutations concordant across tumors from individual patients included BAP1, SMARCA4 and IDH1. Small insertions and deletions (indels) present at the same genome positions among all tumors from individuals included indels in DNA repair genes, CHEK1, ERCC5, ATR and MSH6. Copy number alterations were also similar between all tumors in each patient. In this cohort of multifocal IHC, genomic profiles were concordant across all tumors in each patient, suggesting a common progenitor cell origin, regardless of the location of tumors in the liver. The decision to perform surgery should not be based upon a perceived distinction between IM and SN.

摘要

在多灶性肝内胆管细胞癌 (IHC) 中,肝内转移 (IM) 是手术切除的禁忌症,而卫星结节 (SN) 则不是。然而,目前尚无区分 IM 和 SN 的共识标准。本研究旨在确定手术切除的多灶性 IHC 中的遗传改变和克隆关系。使用针对 201 个癌症相关基因的靶向面板对 34 个空间分离的 IHC 肿瘤进行了下一代测序。文献中提出的 SN 定义为位于同一肝段且距原发肿瘤≤2cm 的结节;IM 定义为位于不同肝段和/或距原发肿瘤>2cm 的结节。来自单个患者的肿瘤之间一致的体细胞点突变包括 BAP1、SMARCA4 和 IDH1。个体所有肿瘤中相同基因组位置存在的小插入和缺失 (indels) 包括 DNA 修复基因、CHEK1、ERCC5、ATR 和 MSH6 中的 indels。每个患者的所有肿瘤之间的拷贝数改变也相似。在这组多灶性 IHC 中,每个患者的所有肿瘤之间的基因组图谱是一致的,这表明存在共同的祖细胞起源,而与肿瘤在肝脏中的位置无关。手术决策不应基于对 IM 和 SN 之间差异的认知。